These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16893070)

  • 1. C5b-9 complement complex in autoimmune demyelination: dual role in neuroinflammation and neuroprotection.
    Rus H; Cudrici C; Niculescu F
    Adv Exp Med Biol; 2006; 586():139-51. PubMed ID: 16893070
    [No Abstract]   [Full Text] [Related]  

  • 2. C5b-9 complement complex in autoimmune demyelination and multiple sclerosis: dual role in neuroinflammation and neuroprotection.
    Rus H; Cudrici C; Niculescu F
    Ann Med; 2005; 37(2):97-104. PubMed ID: 16026117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection.
    Rus H; Cudrici C; Niculescu F; Shin ML
    J Neuroimmunol; 2006 Nov; 180(1-2):9-16. PubMed ID: 16905199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival.
    Tegla CA; Cudrici C; Rus V; Ito T; Vlaicu S; Singh A; Rus H
    J Neuroimmunol; 2009 Aug; 213(1-2):3-11. PubMed ID: 19577811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of complement C5 on apoptosis in experimental autoimmune encephalomyelitis.
    Niculescu T; Weerth S; Niculescu F; Cudrici C; Rus V; Raine CS; Shin ML; Rus H
    J Immunol; 2004 May; 172(9):5702-6. PubMed ID: 15100315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligodendrocyte-specific FADD deletion protects mice from autoimmune-mediated demyelination.
    Mc Guire C; Volckaert T; Wolke U; Sze M; de Rycke R; Waisman A; Prinz M; Beyaert R; Pasparakis M; van Loo G
    J Immunol; 2010 Dec; 185(12):7646-53. PubMed ID: 21068410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory disease: assault on the guardian.
    Ransohoff RM
    Nature; 2007 Jul; 448(7152):421-2. PubMed ID: 17653181
    [No Abstract]   [Full Text] [Related]  

  • 8. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination.
    Storch MK; Piddlesden S; Haltia M; Iivanainen M; Morgan P; Lassmann H
    Ann Neurol; 1998 Apr; 43(4):465-71. PubMed ID: 9546327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury.
    Mead RJ; Singhrao SK; Neal JW; Lassmann H; Morgan BP
    J Immunol; 2002 Jan; 168(1):458-65. PubMed ID: 11751993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The complement system in central nervous system diseases.
    Rus H; Cudrici C; David S; Niculescu F
    Autoimmunity; 2006 Aug; 39(5):395-402. PubMed ID: 16923539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand system.
    Zipp F; Krammer PH; Weller M
    Immunol Today; 1999 Dec; 20(12):550-4. PubMed ID: 10562705
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of the complement system in the pathogenesis of experimental autoimmune encephalomyelitis and multiple sclerosis.
    Terényi N; Prechl J; Erdei A
    Adv Exp Med Biol; 2006; 586():177-88. PubMed ID: 16893072
    [No Abstract]   [Full Text] [Related]  

  • 13. Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis.
    Noorbakhsh F; Tsutsui S; Vergnolle N; Boven LA; Shariat N; Vodjgani M; Warren KG; Andrade-Gordon P; Hollenberg MD; Power C
    J Exp Med; 2006 Feb; 203(2):425-35. PubMed ID: 16476770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligodendrocyte cell death in pathogenesis of multiple sclerosis: Protection of oligodendrocytes from apoptosis by complement.
    Cudrici C; Niculescu T; Niculescu F; Shin ML; Rus H
    J Rehabil Res Dev; 2006; 43(1):123-32. PubMed ID: 16847778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicine: Collateral damage repaired.
    Steinman L
    Nature; 2003 Apr; 422(6933):671-2. PubMed ID: 12700743
    [No Abstract]   [Full Text] [Related]  

  • 16. LINGO-1 antibody ameliorates myelin impairment and spatial memory deficits in experimental autoimmune encephalomyelitis mice.
    Sun JJ; Ren QG; Xu L; Zhang ZJ
    Sci Rep; 2015 Sep; 5():14235. PubMed ID: 26383267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oligodendrocyte apoptosis before immune attack in multiple sclerosis?
    Pender MP
    Ann Neurol; 2005 Jan; 57(1):158; author reply 158-9. PubMed ID: 15622546
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of bcl-2 and mediated by inhibition of caspase-3 activation.
    Soane L; Rus H; Niculescu F; Shin ML
    J Immunol; 1999 Dec; 163(11):6132-8. PubMed ID: 10570303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond.
    Aharoni R
    Autoimmun Rev; 2013 Mar; 12(5):543-53. PubMed ID: 23051633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective agents: cannabinoids.
    Sánchez AJ; García-Merino A
    Clin Immunol; 2012 Jan; 142(1):57-67. PubMed ID: 21420365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.